Elevated serum alkaline phosphatase (ALP) levels are associated with increased mortality in patients with nondialysis CKD. Previous studies have shown that elevated ALP is associated with higher ...
The IDEAL trial met its primary endpoint, showing that seladelpar significantly improved ALP normalization compared with placebo at week 52. Positive topline data were announced from a phase 3 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results